Why Native Immunogens Outperform Recombinant Alternatives
Antibodies recognize 3D shapes, not 2D sequences. When you immunize with a recombinant protein that lacks native folding, glycosylation, or post-translational modifications, you get antibodies optimized for a target that doesn't exist in real samples.
The result? Antibodies that fail in Western blots, miss targets in immunohistochemistry, or show unexpected cross-reactivity in diagnostic applications.
Athens immunogen-grade proteins eliminate this problem at the source:
- Native conformation – antibodies raised against native immunogens recognize the same epitopes present in clinical samples, tissue lysates, and diagnostic targets
- High purity (≥98%) – contaminant proteins trigger unacceptable responses that dilute your yield of target-specific antibodies and complicate downstream screening
- Mass spec identity confirmation – confirms you're immunizing against what you think you are, not a co-purified contaminant or degradation product
- Lot-to-lot consistency – same immunogen, same response, same antibody characteristics across production campaigns
Antibody manufacturers worldwide trust Athens proteins. We work directly with production teams to match specifications to protocols.
Want a deeper look?
See how Athens immunogens support antibody manufacturing programs worldwide.
*1. Boottanun, et al. An improved evanescent fluorescence scanner suitable for high-resolution glycome mapping of formalin-fixed paraffin-embedded tissue sections. Anal Bioanal Chem 415, 2023, 6975–6984. https://doi.org/10.1007/s00216-023-04824-2
*2. Correia, et al. Sedimentation velocity FDS studies of antibodies in pooled human serum. Eur Biophys J 52, 2023, 321–332. https://doi.org/10.1007/s00249-023-01652-1
*3. Mayner, et al. Heterogeneous expression of alternatively spliced lncRNA mediates vascular smooth cell plasticity. Proc Natl Acad Sci U S A 120, 2023, e2217122120. https://doi.org/10.1073/pnas.2217122120
